Ardelyx scraps PhIII drug after researchers raise a safety issue for hyperkalemia patients
The roller coaster ride at Ardelyx is continuing today with news that one of their late-stage assets is being scrapped.
With their lead drug tenapanor being slowly guided to regulators and a hoped-for market showdown for irritable bowel syndrome, Ardelyx $ARDX reported that it has decided to scuttle its Phase III program for RDX7675 in patients with hyperkalemia after tracking a safety issue — drug-related reduction in serum bicarbonate, which can trigger a decision to stop treatment — which essentially blew up its plans to market this treatment for chronic cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.